Thromboembolic Events in JAK inhibitors: A Pharmacovigilance Study From 2012 to 2021 Based on FAERS.
Sign Up to like & getrecommendations! Published in 2022 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15361
Abstract: INTRODUCTION As a new type of drug developed rapidly in recent years, Janus kinase inhibitors (JAKinibs) have caused controversy due to possible adverse reactions of thromboembolism. The aim of this study was to analyze and… read more here.
Keywords: thrombosis ror025; ror025; study; ror025 ic025 ... See more keywords
Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.817662
Abstract: Backgrounds: Immune checkpoint inhibitors (ICIs) are considered cornerstones of oncology treatment with durable anti-tumor efficacy, but the increasing use of ICIs is associated with the risk of developing immune-related adverse events (irAEs). Although ICI-associated pancreatic… read more here.
Keywords: pancreatic aes; adverse events; ici associated; ror025 ic025 ... See more keywords